Abstract
Src family kinases (SFKs) are a group of non-receptor tyrosine kinases whose activity is involved in the regulation of cellular morphology, motility, proliferation and survival. An aberrant activation and expression of these kinases contribute to the pathogenesis and progression of a broad range of diseases, such as a large number of solid tumors, various hematological malignancies and some neuronal pathologies. The search for SFK inhibitors is therefore a promising research topic in medicinal chemistry. Computational studies such as receptor-based and/or ligand-based virtual screening, docking, and molecular modeling proved to be a powerful tool for identifying new SFKs inhibitors. In this review we report and analyze the main examples of computational approaches that allowed the identification of new SFKs ligands and the optimization of either activity and pharmacokinetic profile of lead compounds.
Keywords: c-Src, Fyn, Hck, Lck, Lyn, Src family kinases, virtual screening, yes.
Current Medicinal Chemistry
Title:Computational Approaches for the Identification and Optimization of Src Family Kinases Inhibitors
Volume: 21 Issue: 28
Author(s): G. Poli, A. Martinelli and T. Tuccinardi
Affiliation:
Keywords: c-Src, Fyn, Hck, Lck, Lyn, Src family kinases, virtual screening, yes.
Abstract: Src family kinases (SFKs) are a group of non-receptor tyrosine kinases whose activity is involved in the regulation of cellular morphology, motility, proliferation and survival. An aberrant activation and expression of these kinases contribute to the pathogenesis and progression of a broad range of diseases, such as a large number of solid tumors, various hematological malignancies and some neuronal pathologies. The search for SFK inhibitors is therefore a promising research topic in medicinal chemistry. Computational studies such as receptor-based and/or ligand-based virtual screening, docking, and molecular modeling proved to be a powerful tool for identifying new SFKs inhibitors. In this review we report and analyze the main examples of computational approaches that allowed the identification of new SFKs ligands and the optimization of either activity and pharmacokinetic profile of lead compounds.
Export Options
About this article
Cite this article as:
Poli G., Martinelli A. and Tuccinardi T., Computational Approaches for the Identification and Optimization of Src Family Kinases Inhibitors, Current Medicinal Chemistry 2014; 21 (28) . https://dx.doi.org/10.2174/0929867321666140706144419
DOI https://dx.doi.org/10.2174/0929867321666140706144419 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Hydroxamate and Anilide Derivatives as Potent Histone Deacetylase Inhibitors: Synthesis and Antiproliferative Evaluation
Current Medicinal Chemistry A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities
Current Pharmaceutical Design Liquid-Crystalline Nanodispersions Containing Monoolein for Photodynamic Therapy of Skin Diseases: A Mini-Review
Current Nanoscience Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Honey, Health and Longevity
Current Aging Science Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Patent Selections
Recent Patents on Biomarkers Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A
Anti-Cancer Agents in Medicinal Chemistry Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews The Medical Potential of Antimicrobial Peptides from Insects
Current Topics in Medicinal Chemistry Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology TGF-β in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma
Current Pharmaceutical Design The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy